Skip to content

Monthly Archives: July 2013

Use of White Blood Cell Growth Factors in Cancer Patients with Neutropenia


This post is based on the guideline of American Society of Clinical Oncology and Infectious Diseases Society of America. Prophylactic CSF Administration Prophylacitc CSF is recommended for the prevention of FN in patients who have a high risk of FN based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. New clinical […]

The Management of Acute Lymphoblastic Leukemia in Adults (Stratetgies)


Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. ALL is a heterogeneous disease, both in terms of its pathology and the populations that it affects. Prognostic Factors and Risk Categories Several factors determine the prognosis […]

Antimicrobial Therapy in Neutropenic and Fever Patients With Cancer (Risk Evaluation and Initial Therapy)


This thread is based on the guideline from IDSA (Infectious Diseases Society of America) and ASCO (American Society of Clinical Oncology), which provides a general approach to the management of patients with cancer who have neutropenia and present with fever, and it gives special attention to antimicrobial management. Fever occurs frequently during chemotherapy-induced neutropenia: 10%-50% […]

Anti-infection Prophylaxis in Cancer Patients With Neutropenia (Drug Selection)


Because evidence was unavailable from trials limited to outpatients, the ASCO Panel considered evidence from studies on inpatients or mixed populations, and the recommendatons are based on the summarized evidence and Panel members’ expert opinion. Antibacterial Prophylaxis Majority of randomly assigned patients in studies were hospitalized and treated for hematolgic malignancies. Taken together, evidence shows […]

The Management of Therapy-related Acute Meyloid Leukemia


Until recently, the term “secondary leukemia” broadly included any AML with a history of prior malignancy as well as patients with any antecedent hematologic disorder and, in some series, any patient who presented with unfavorable cytogenetics. Among therapy-related AML patients, 70% present with abnormalities of chromosome 5 or 7, which is the most typical presentation […]